Compare ARK Genomic Revolution ETF (ARKG) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while iShares Broad USD Investment Grade Corporate Bond trades at $50.71. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| ARKG | USIG | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $43.57 | $52.69 |
52-Week Low | $23.09 | $50.56 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
USIG trades at $50.705, down 0.15% on the day, with technical indicators showing a bearish trend from moving averages while oscillators are neutral. Recent corporate actions include dividend payments, with the latest being $0.20 paid on 07 Jul 2026. Short interest surged 63.4% in April 2026, indicating increased bearish sentiment among traders, per Defense World on 2026-04-27.
The outlook remains cautious due to weak technical signals and rising short interest, though dividends provide income support. Key risks include market volatility and institutional selling, as seen with Fifth Third Securities reducing its stake by 54.7% in Q1 2026. Investors should weigh income stability against bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
